What is the difference between BRCA1 and BRCA2?
BRCA1 and BRCA2 are different tumour suppressor genes that, when mutated, increase the risk of developing breast and other cancers. Although both are inherited in the same way, they differ in gene structure, cancer risk profiles, and implications for treatment and screening.
Pro Tip: BRCA1 mutation carriers should discuss earlier oophorectomy timing with clinicians due to higher ovarian cancer risk before age 40.
Understanding BRCA Genes and Their Role in Breast Cancer
BRCA1 and BRCA2 are part of the body’s natural defence against cancer. They code for proteins that help repair DNA damage, particularly in dividing cells such as those in breast and ovarian tissue. When functioning normally, these genes help maintain cellular integrity.
Mutations in either gene reduce the cell’s ability to repair DNA. This can allow errors to accumulate over time, increasing the likelihood that cells grow in an uncontrolled manner. These mutations are inherited in an autosomal dominant pattern, which means that a single faulty copy from either parent can increase cancer risk.
BRCA mutations most commonly affect breast and ovarian tissue but may also influence risks for prostate, pancreatic, and other cancers. Importantly, not all BRCA mutations have the same implications. Some variants have uncertain significance and do not always increase cancer risk. This is why genetic counselling is important.
A common misconception is that only those with a strong family history need to consider BRCA testing. While family history remains a key criterion, some individuals with BRCA mutations have no known familial link. National guidelines, such as those from NICE, provide structured criteria for when referral to genomic medicine services is appropriate.
BRCA1 vs BRCA2: Key Genetic Differences
Although often discussed together, BRCA1 and BRCA2 are distinct genes with differing roles and implications.
- Location:
- BRCA1 sits on chromosome 17 (17q21).
- BRCA2 is located on chromosome 13 (13q12.3).
- Gene Structure and Repair Function:
- BRCA1 plays a broader role in DNA damage recognition.
- BRCA2 specifically assists in repairing double-strand breaks using a process called homologous recombination.
- Mutation Spectrum:
- BRCA1 mutations often carry higher risk for certain cancer types.
- BRCA2 mutations may result in a wider range of variant types, sometimes with lesser penetrance.
- Clinical Testing:
- Both genes are sequenced separately because their mutation patterns differ.
- Variant classification systems, supported by bioinformatics tools developed through efforts like the Human Genome Project, guide clinical interpretation.
Understanding these differences helps determine treatment plans, screening strategies, and conversations around risk.
Book a Genetics Consultation
Cancer Risks Associated with BRCA1 and BRCA2
A BRCA mutation increases the likelihood of developing certain cancers, but the risk level and pattern vary by gene.
- Breast Cancer:
- BRCA1 carriers have a lifetime breast cancer risk estimated between 60 and 80 percent.
- BRCA2 carriers face a risk in the range of 50 to 70 percent.
- Ovarian Cancer:
- BRCA1 mutations carry a significant ovarian cancer risk, often estimated around 40 to 60 percent.
- BRCA2 risk is lower, generally ranging from 10 to 30 percent.
- Age of Onset:
- BRCA1-associated breast cancers tend to occur at younger ages, often before 40.
- BRCA2-related cancers may appear later and sometimes follow a different clinical course.
- Male Breast Cancer and Prostate Cancer:
- BRCA2 is more strongly associated with male breast cancer and prostate cancer.
- BRCA1 carries lower but still elevated risk for these cancers.
- Public Perception vs Actual Risk: Risk estimates often circulate without context, leading to anxiety or overestimation. Tools like the BOADICEA model and NHS Predict provide personalised risk assessments to support decisions.
Implications for Screening and Surveillance
A known BRCA mutation alters the recommended approach to breast cancer screening. Surveillance is typically intensified and begins earlier than population screening guidelines suggest.
- Start Age:
- Screening for BRCA1 and BRCA2 carriers typically starts at age 30 or even earlier if there is a strong family history.
- Imaging Methods:
- Annual MRI scans are commonly recommended due to higher sensitivity in younger breast tissue.
- Mammography may be added from the mid-thirties, depending on breast density and other factors.
- Frequency:
- Annual imaging, often alternating between MRI and mammography, is normal practice.
- Surveillance intervals may be customised based on age, previous findings and changes in clinical presentation.
- Clinical Examination:
- Regular consultant reviews and patient awareness of breast changes remain core components of monitoring.
- BRCA1 carriers are prioritised for earlier and more aggressive surveillance due to higher cancer risk at younger ages.
- Self-Examination Guidance:
- While self-examination is encouraged, structured screening remains the foundation of early detection.
Surveillance should follow protocols supported by NICE and guided by experienced multidisciplinary teams.
Pro Tip: Variant of Uncertain Significance (VUS) results require careful interpretation with genetic counselling rather than immediate assumptions about risk.
Surgical Options and Risk-Reducing Strategies
For some BRCA carriers, surgery may be considered to reduce cancer risk. The specific approach is influenced by gene type, age, family history and personal preference.
Preventive Mastectomy
A risk-reducing bilateral mastectomy significantly lowers the likelihood of breast cancer. It is more commonly considered by BRCA1 carriers due to a typically earlier age of onset. Aesthetic outcomes, symmetry and reconstruction options are integral to planning. These surgeries should be carried out in settings equipped for oncoplastic techniques, combining cancer safety with appearance considerations.
Oophorectomy Timing
BRCA1 carriers are often advised to consider bilateral salpingo-oophorectomy between ages 35 and 40, once childbearing is complete. BRCA2 carriers may be advised to delay this to around age 40 to 45, reflecting their relatively lower ovarian cancer risk.
Breast Reconstruction
Reconstruction can be performed at the same time as mastectomy or later, depending on preference and clinical context. Decisions balance oncological safety with physical and psychological wellbeing. Options include implant-based reconstruction or autologous tissue methods. Planning involves consultation with surgeons experienced in both cancer and reconstructive techniques, such as those offered by D B Ghosh Breast Surgeon Specialist in Cancer and Cosmetic Surgery Harley Street London.
Impact on Family and Genetic Counselling
A BRCA mutation affects the individual but also their relatives, many of whom may share the gene.
Inheritance and Family Testing
BRCA mutations are passed down in an autosomal dominant fashion, which means that each child has a 50 percent chance of inheriting the mutation. Relatives of a known carrier should consider genetic counselling to understand their own risk.
Cascade Testing
Testing often begins with the family member who has the highest likelihood of carrying the mutation. If a mutation is confirmed, targeted testing of relatives is offered.
Role of Genetic Counselling
Specialist genetic counselling helps individuals understand what testing means, what the results might show, and how to decide whether to proceed. Counselling is not limited to scientific information; it also covers emotional and ethical considerations around sharing information with family members.
Communication Within Families
Discussing genetic risk is a personal, sometimes complex process. Clinicians can support this by providing letters, resources and guidance to help individuals talk through implications with relatives while maintaining autonomy and sensitivity.
Visit the One Stop Breast Clinic
Treatment Considerations for BRCA-Positive Breast Cancer
When breast cancer develops in someone with a BRCA mutation, the treatment plan may incorporate certain additional considerations.
Chemotherapy Sensitivity
Some BRCA-related cancers, particularly those associated with BRCA1, are more sensitive to platinum-based chemotherapy agents. These treatments may be offered based on tumour biology and response prediction.
Targeted Therapies
PARP inhibitors are a targeted treatment option in certain BRCA-mutated breast cancers. These medications exploit the underlying DNA repair weakness in tumour cells, aiming to selectively impair cancer growth while sparing normal cells. Their use is determined through consultant-led multidisciplinary discussions in line with NICE oncology guidelines.
Surgical Implications
The presence of a BRCA mutation often influences surgical planning. For instance, risk-reducing mastectomy may be discussed even in early-stage cancers. This is particularly relevant in younger patients or where there is bilateral disease risk.
Ongoing Monitoring
Following treatment, BRCA-positive individuals may require more intensive or customised follow-up. Surveillance strategies look beyond the primary cancer to include contralateral breast monitoring and secondary risk management.
Treatment decisions should always be guided by a multidisciplinary team and crafted to match the patient’s diagnosis, values and long-term goals.
When and Why to Consider BRCA Testing
BRCA testing is not necessary for everyone. Clinical criteria guide decisions about when testing is appropriate.
Eligibility Criteria
Testing may be recommended if a person has:
- A personal or family history of breast cancer diagnosed at a young age
- Ovarian cancer in the family
- Male breast cancer in close relatives
- Multiple relatives with breast or other related cancers
- Ashkenazi Jewish ancestry, where certain BRCA mutations are more common
These criteria align with NICE CG164 guidance.
The Testing Process
Testing involves a blood or saliva sample and requires informed consent. Results can take several weeks and are interpreted with support from genetics professionals.
Possible Results
- Positive: A mutation is identified that increases cancer risk.
- Negative: No mutation is found, though risk may still be evaluated based on family history.
- Uncertain (VUS): A variant is found, but its clinical significance is unknown. Further family studies may help clarify its meaning.
Role of the One Stop Breast Clinic
Integrated services, such as those at the Rapid Diagnostic Centre, 146 Harley St, London W1G 7LD, allow patients to undergo assessment, imaging and biopsy in a single visit. When a BRCA mutation is suspected, this model streamlines the pathway to genetic counselling and testing. It brings together diagnosis and future planning under a consultant-led framework, which reduces uncertainty and aids informed decisions.
Understanding the distinctions between BRCA1 and BRCA2 helps patients and families make well-informed decisions. Whether weighing screening options, considering surgery or planning treatment, these insights support personalised, medically grounded care at every step.
